|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
EXIMIAS Announces Study Results
of THYMITAQ(R) in Patients With Advanced Pancreatic Cancer Presented
at ASCO EXIMIAS Pharmaceutical Corporation presented yesterday at the American Society of Clinical Oncology meeting that THYMITAQ® (nolatrexed dihydrochloride) may have promising activity contributing to disease stabilization in pancreatic cancer. Based on activity in Phase I studies, THYMITAQ® was evaluated in a multicenter Phase II trial in patients with metastatic pancreatic cancer. THYMITAQ® is a novel antifolate that exerts its anticancer activity through direct inhibition of thymidylate synthase. ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||